Gossamer Bio, INC Form 4 insider transactions

Gossamer Bio, Inc. Director Skye Drynan was granted 115,000 stock options with an exercise price of $1.36, vesting on the first anniversary of the grant date or the next annual meeting.

Caryn Peterson, EVP of Regulatory Affairs at Gossamer Bio, Inc., was granted 440,000 stock options on March 4, 2025.

Christian Waage, EVP of Tech Ops and Admin at Gossamer Bio, Inc., acquired 440,000 stock options on March 4, 2025.

Robert Paul Smith JR, Chief Commercial Officer of Gossamer Bio, Inc., acquired 572,000 stock options on March 4, 2025, at an exercise price of $1.13.

Richard Aranda, Chief Medical Officer of Gossamer Bio, Inc., reports the acquisition of 572,000 stock options on March 4, 2025.

Bryan Giraudo, COO/CFO of Gossamer Bio, Inc., reports the acquisition of stock options for 638,000 shares of common stock on March 4, 2025.

Faheem Hasnain, President & CEO of Gossamer Bio, Inc., was granted 1,540,000 stock options on March 4, 2025, according to a Form 4 filing.

Richard Aranda, Chief Medical Officer of Gossamer Bio, Inc., sold 1,908 shares of common stock on June 24, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Faheem Hasnain, President & CEO of Gossamer Bio, Inc., recently purchased 372,000 shares of common stock at a price of $0.6728 per share.

Bryan Giraudo, COO/CFO of Gossamer Bio, Inc., purchased 100,000 shares of common stock at a price of $0.5911 per share on June 18, 2024.

Robert Paul Smith JR, Chief Commercial Officer of Gossamer Bio, Inc., acquired 25,000 shares of common stock at $0.602 per share on June 17, 2024.

Director John D. Quisel acquired 115,000 non-qualified stock options in Gossamer Bio, Inc. on June 6, 2024.

Director Sandra Milligan acquired 115,000 non-qualified stock options in Gossamer Bio, Inc. on June 6, 2024, as part of the Non-Employee Director Compensation Program.

Director Russell J. Cox acquired 115,000 non-qualified stock options in Gossamer Bio, Inc. on June 6, 2024, as part of the Non-Employee Director Compensation Program.

Director Thomas O. Daniel acquired 115,000 non-qualified stock options in Gossamer Bio, Inc. on June 6, 2024, as part of the Non-Employee Director Compensation Program.

Executive VP of Technology Operations and Administration at Gossamer Bio, Christian Waage, sold shares to cover tax obligations related to vesting restricted stock units.

Bryan Giraudo, COO/CFO of Gossamer Bio, Inc., sold 6,430 shares of common stock on March 27, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Gossamer Bio's CEO, Faheem Hasnain, sold shares of common stock to cover tax obligations related to vesting restricted stock units.

Richard Aranda, Chief Medical Officer of Gossamer Bio, Inc., sold 4,018 shares of common stock on March 18, 2024, to cover tax obligations related to vesting restricted stock units.

Caryn Peterson, EVP of Regulatory Affairs at Gossamer Bio, sold 4,018 shares of common stock to cover tax obligations related to vesting restricted stock units.

Director Skye Drynan acquired 230,000 stock options in Gossamer Bio, Inc. on March 11, 2024, at an exercise price of $1.34.

Director Steven D. Nathan acquired 230,000 stock options in Gossamer Bio, Inc. on March 11, 2024.